Metastatic prostate cancer presenting as tumour-induced osteomalacia.
Awo Akosua Kesewa LaymanShivam JoshiSanjeev ShahPublished in: BMJ case reports (2019)
Tumour-induced osteomalacia (TIO), or oncogenic osteomalacia, is a paraneoplastic syndrome marked by hypophosphataemia, renal phosphate wasting, bone pain, weakness, and fractures. The syndrome has been reported with both benign and malignant tumours including parotid gland basal cell tumours, thyroid carcinomas, colon adenocarcinomas, and prostate cancer. Often, the syndrome is marked by an insidious course during which patients present with generalised bony pain and weakness, which do not resolve until the underlying tumour is identified and treated. We present a case of a patient with Parkinson's disease whose subacute weakness, lower extremity paresis, and renal phosphate wasting led to the synchronous diagnosis of metastatic prostate adenocarcinoma and TIO.
Keyphrases
- prostate cancer
- case report
- squamous cell carcinoma
- chronic pain
- radical prostatectomy
- small cell lung cancer
- newly diagnosed
- high glucose
- diabetic rats
- end stage renal disease
- pain management
- ejection fraction
- drug induced
- neuropathic pain
- quantum dots
- chronic kidney disease
- single cell
- cell therapy
- radiation therapy
- transcription factor
- patient reported outcomes
- oxidative stress
- bone mineral density
- postoperative pain
- bone marrow
- patient reported
- postmenopausal women
- squamous cell